Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia

被引:122
作者
Doab, A
Treloar, C
Dore, GJ
机构
[1] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Darlinghurst, NSW 2010, Australia
[2] Univ New S Wales, Natl Ctr HIV Social Res, Darlinghurst, NSW 2010, Australia
关键词
D O I
10.1086/427446
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Despite recent improvements in outcomes of treatment for infection with hepatitis C virus (HCV), very few current injection drug users (IDUs) have access to treatment programs. We examined the natural history of and treatment knowledge about HCV infection and barriers and willingness to seek treatment for HCV infection. A convenience sample of current IDUs (n =100) with self-reported HCV-positive status drawn from a primary health facility and methadone clinic in inner Sydney completed an interviewer-administered questionnaire. Participants had a reasonable knowledge of the natural history of HCV infection but poorer knowledge of treatment for HCV infection. Most believed that being a current IDU was an exclusion criterion for treatment. Despite this, 70%-80% of IDUs reported that they would consider treatment under current scenarios in Australia: requirement for liver biopsy, subcutaneous injections, common adverse effects, and 40% efficacy. Study participants at the methadone clinic had higher levels of consideration of treatment. These findings support the development of specific education programs regarding treatment for HCV infection for current IDUs.
引用
收藏
页码:S313 / S320
页数:8
相关论文
共 20 条
  • [1] Treatment of hepatitis C infection in injection drug users
    Backmund, M
    Meyer, K
    Von Zielonka, M
    Eichenlaub, D
    [J]. HEPATOLOGY, 2001, 34 (01) : 188 - 193
  • [2] Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment
    Best, D
    Noble, A
    Finch, E
    Gossop, M
    Sidwell, C
    Strang, J
    [J]. BRITISH MEDICAL JOURNAL, 1999, 319 (7205) : 290 - 291
  • [3] Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection
    Danta, M
    Dore, GJ
    Hennessy, L
    Li, YM
    Vickers, CR
    Harley, H
    Ngu, M
    Reed, W
    Desmond, PV
    Sievert, W
    Farrell, GC
    Kaldor, JM
    Batey, RG
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2002, 177 (05) : 240 - 245
  • [4] Treatment of chronic hepatitis C in active drug users
    Davis, GL
    Rodrigue, JR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) : 215 - 217
  • [5] Epidemiology of hepatitis C virus infection in Australia
    Dore, GJ
    Law, M
    MacDonald, M
    Kaldor, JM
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2003, 26 (02) : 171 - 184
  • [6] Is severe liver disease a common outcome for people with chronic hepatitis C?
    Dore, GJ
    Freeman, AJ
    Law, M
    Kaldor, JM
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (04) : 423 - 430
  • [7] Prevention and treatment of hepatitis C in injection drug users
    Edlin, BR
    [J]. HEPATOLOGY, 2002, 36 (05) : S210 - S219
  • [8] Predicting progression to cirrhosis in chronic hepatitis C virus infection
    Freeman, AJ
    Law, MG
    Kaldor, JM
    Dore, GJ
    [J]. JOURNAL OF VIRAL HEPATITIS, 2003, 10 (04) : 285 - 293
  • [9] Estimating progression to cirrhosis in chronic hepatitis C virus infection
    Freeman, AJ
    Dore, GJ
    Law, MG
    Thorpe, M
    Von Overbeck, J
    Lloyd, AR
    Marinos, G
    Kaldor, JM
    [J]. HEPATOLOGY, 2001, 34 (04) : 809 - 816
  • [10] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried, MW
    Shiffman, ML
    Reddy, KR
    Smith, C
    Marinos, G
    Goncales, FL
    Haussinger, D
    Diago, M
    Carosi, G
    Dhumeaux, D
    Craxi, A
    Lin, A
    Hoffman, J
    Yu, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) : 975 - 982